Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Sold by Guggenheim Capital LLC

Guggenheim Capital LLC trimmed its holdings in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) by 11.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,961 shares of the company’s stock after selling 4,392 shares during the quarter. Guggenheim Capital LLC’s holdings in Revolution Medicines were worth $1,529,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of RVMD. Vanguard Group Inc. raised its stake in shares of Revolution Medicines by 14.7% in the 4th quarter. Vanguard Group Inc. now owns 17,096,455 shares of the company’s stock valued at $747,799,000 after acquiring an additional 2,185,082 shares during the period. FMR LLC raised its position in Revolution Medicines by 14.7% in the fourth quarter. FMR LLC now owns 6,742,083 shares of the company’s stock valued at $294,899,000 after purchasing an additional 866,190 shares during the period. Geode Capital Management LLC lifted its stake in Revolution Medicines by 12.7% during the fourth quarter. Geode Capital Management LLC now owns 4,086,199 shares of the company’s stock worth $180,171,000 after purchasing an additional 459,174 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Revolution Medicines by 9.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,931,114 shares of the company’s stock worth $84,467,000 after purchasing an additional 167,997 shares in the last quarter. Finally, Lord Abbett & CO. LLC purchased a new position in shares of Revolution Medicines during the third quarter worth $83,082,000. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Revolution Medicines

In other news, CFO Jack Anders sold 1,864 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $72,770.56. Following the completion of the sale, the chief financial officer now directly owns 115,006 shares of the company’s stock, valued at approximately $4,489,834.24. The trade was a 1.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark A. Goldsmith sold 11,738 shares of Revolution Medicines stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $458,251.52. Following the transaction, the insider now directly owns 441,564 shares in the company, valued at approximately $17,238,658.56. This trade represents a 2.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 16,660 shares of company stock valued at $650,406 over the last ninety days. Insiders own 8.00% of the company’s stock.

Revolution Medicines Stock Performance

RVMD opened at $36.56 on Tuesday. Revolution Medicines, Inc. has a one year low of $29.17 and a one year high of $62.40. The company has a market cap of $6.80 billion, a P/E ratio of -10.18 and a beta of 1.37. The business’s 50-day simple moving average is $37.68 and its 200-day simple moving average is $44.32.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.11). As a group, analysts predict that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on RVMD shares. HC Wainwright increased their target price on Revolution Medicines from $72.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, March 3rd. Needham & Company LLC reissued a “buy” rating and set a $59.00 price target on shares of Revolution Medicines in a research report on Tuesday, April 8th. Wedbush restated an “outperform” rating and issued a $67.00 price objective on shares of Revolution Medicines in a report on Thursday, February 27th. UBS Group increased their target price on shares of Revolution Medicines from $65.00 to $71.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Finally, Stifel Nicolaus dropped their price target on shares of Revolution Medicines from $78.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $66.67.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.